TrialAnnals of the rheumatic diseases2015

A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease.

Cailin H Sibley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.